Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080 is registered in ClinicalTrials.gov with Incyclix Bio as lead sponsor.

NCT NCT05735080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer
Lead sponsor
Incyclix Bio
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 28, 2023
Completion date
September 30, 2027
Enrollment
150 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, breast cancer, breast cancer metastatic, ccne1 amplification, hormone receptor positive tumor, human epidermal growth factor 2 negative carcinoma of breast, metastatic cancer, ovarian cancer, solid tumor